Mechanical performance and healing patterns of the novel sirolimus-eluting bioresorbable Fantom scaffold: 6-month and 9-month follow-up by optical coherence tomography in the FANTOM II study

Simonsen, Jo Krogsgaard; Holck, Emil Nielsen; Carrié, Didier; Frey, Norbert; Lutz, Matthias; Weber-Albers, Joachim; Dudek, Dariusz; Chevalier, Bernard; Daemen, Joost; Dijkstra, Jouke; Maule, Camilla Fox; Neghabat, Omeed; Lassen, Jens Flensted; Anderson, Jeffrey; Christiansen, Evald Hoj; Holm, Niels Ramsing; Abizaid, Alexandre.
Open Heart ; 6(1): 1-9, Fev. 2019. ilustração, tabela, gráfico
Artículo en Inglés | SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1024948

Documentos relacionados

  1. FANTOM II Trial: safety and performance study of the fantom sirolimus-eluting bioresorbable coronary scaffold: first report: final 5-year clinical outcomes
  2. A systematic review and meta-analysis of sirolimus-eluting stents for treatment of below-the-knee arterial disease.
  3. Predictors of 10-Year Stent-Related Adverse Outcomes after Coronary Drug-Eluting Stent Implantation: The Importance of Stent Size.
  4. Vascular Injury After Stenting　- Insights of Systemic Mechanisms of Vascular Repair.
  5. Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis.
  6. Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial.
  7. Early healing after treatment of coronary lesions by thin strut everolimus, or thicker strut biolimus eluting bioabsorbable polymer stents: The SORT-OUT VIII OCT study.
  8. Improved Outcomes of Combined Main Branch Stenting and Side Branch Drug-Coated Balloon versus Two-Stent Strategy in Patients with Left Main Bifurcation Lesions.
  9. Five-year angiographic, OCT and clinical outcomes of a randomized comparison of everolimus and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
  10. Safety of drug-eluting stents for stenting patent arterial duct in neonates.